COST-UTILITY ANALYSIS OF LIRAGLUTIDE VERSUS GLIMEPIRIDE AS ADD-ON TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES IN CHINA

被引：1
|
作者：
Gao, L. [1 ]
Li, S. C. [1 ]
机构：
[1] Univ Newcastle, Callaghan, NSW 2308, Australia
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.358
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A663 / A663
页数：1
相关论文
共 50 条
  • [21] Liraglutide add-on to metformin improves postprandial glucose control compared with metformin monotherapy in patients with Type 2 diabetes: posthoc analysis of the Liraglutide Effect and Action in Diabetes (LEAD)2 study
    Stephens, J. W.
    Fulcher, G.
    Matthews, D. R.
    Nauck, M. A.
    Svendsen, C. B.
    Donsmark, M.
    Garber, A.
    DIABETIC MEDICINE, 2014, 31 : 178 - 178
  • [22] DIABETES Add-on to metformin in T2DM-linagliptin or glimepiride?
    Christensen, Mikkel
    Knop, Filip K.
    NATURE REVIEWS ENDOCRINOLOGY, 2012, 8 (10) : 576 - 578
  • [23] Vildagliptin Versus α-Glucosidase Inhibitor as Add-On to Metformin for Type 2 Diabetes: Subgroup Analysis of the China Prospective Diabetes Study
    Chen, Yulong
    Li, Quanmin
    Han, Ying
    Ji, Hongmei
    Gu, Mingjun
    Bian, Rongwen
    Ding, Weiguang
    Cheng, Jian
    Mu, Yiming
    DIABETES THERAPY, 2020, 11 (01) : 247 - 257
  • [24] Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes
    Ericsson, Asa
    Glah, Divina
    Lorenzi, Maria
    Jansen, Jeroen P.
    Fridhammar, Adam
    PLOS ONE, 2018, 13 (02):
  • [25] Vildagliptin Versus α-Glucosidase Inhibitor as Add-On to Metformin for Type 2 Diabetes: Subgroup Analysis of the China Prospective Diabetes Study
    Yulong Chen
    Quanmin Li
    Ying Han
    Hongmei Ji
    Mingjun Gu
    Rongwen Bian
    Weiguang Ding
    Jian Cheng
    Yiming Mu
    Diabetes Therapy, 2020, 11 : 247 - 257
  • [26] ECONOMIC EVALUATION OF VILDAGLIPTIN COMPARED TO GLIMEPIRIDE AS ADD-ON TO METFORMIN FOR THE TREATMENT OF DIABETES MELLITUS TYPE 2 PATIENTS IN GREECE
    Hatzikou, M.
    Rombopoulos, G.
    Yfantopoulos, J.
    VALUE IN HEALTH, 2012, 15 (07) : A501 - A501
  • [27] Assessment of empagliflozin add-on therapy to metformin and glimepiride in patients with inadequately controlled type-2 diabetes mellitus
    Jawed, Bilal
    Ahmed, Shadab
    Abbas, Syed Qamar
    Ahmed, Zeeshan
    Andleeb, Shomaiza
    Ahmad, Salman Ashfaq
    Asif, Muhammad
    Akhter, Erum
    Ahmed, Salman
    Hussain, Muhammad Waleed
    Iqbal, Adnan
    Ishaqui, Azfar Athar
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 35 (06) : 1733 - 1738
  • [28] Add-on therapies to metformin for type 2 diabetes
    Shomali, Mansur
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (01) : 47 - 62
  • [29] COST-EFFECTIVENESS ANALYSIS OF LINAGLIPTIN VERSUS SULFONYLUREA AS ADD-ON TREATMENT TO METFORMIN FOR THE TREATMENT OF DIABETES MELLITUS TYPE 2 PATIENTS IN INDONESIA
    Endarti, D.
    Kristin, E.
    Pratiwi, W. R.
    Pinzon, R. T.
    Nugrahaningsih, D. A.
    Yasmina, A.
    Febrinasari, R. P.
    VALUE IN HEALTH, 2018, 21 : S39 - S39
  • [30] The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus
    Gordon, Jason
    McEwan, Phil
    Hurst, Michael
    Puelles, Jorge
    DIABETES THERAPY, 2016, 7 (04) : 825 - 845
12345